^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AVID100
i
Other names: AVID100, AVID 100
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
Related drugs:
3years
AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov)
P1a, N=49, Terminated, Formation Biologics | N=90 --> 49 | Active, not recruiting --> Terminated; lack of efficacy
Clinical • Enrollment change • Trial termination
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR overexpression
|
AVID100
over3years
AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov)
P1a, N=90, Active, not recruiting, Formation Biologics | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR overexpression
|
AVID100
Share via
